What We Do
Discover
new approaches to developing vaccines and other means of preventing HIV.
Accelerate
translational and clinical research through our laboratories in the U.S., India, and the U.K.
Build Capacity
in-country for researching vaccine candidates while strengthening local public health and scientific expertise.
Partner
with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.
Share
IAVI’s resources with other innovators to help the HIV community as a whole succeed.
Extend
IAVI’s core capabilities to solving disease prevention and treatment challenges.
Latest News from IAVI
IAVI, University of Oslo, & THSTI to Partner for HIV Prevention R&D
Technology transfer and international cooperation could lead to long-lived HIV protection for women and girls in developing countries
Donor Spotlight: The Norwegian Government
IAVI recognizes the Norwegian government and its Norwegian Development Agency (Norad) for its continued commitment to HIV vaccine research and applauds its dedication to global health research and development.
IAVI Partners in Snakebite Treatment Consortium
Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year.
IAVI Report: Special issue on HIV vaccine science in Africa, for Africa
The issue was inspired by the elegant science being produced by scientists in Africa and the scientific capacity being built via IAVI’s ADVANCE program.
Phase I Trial of Native-like HIV Env Trimer
Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein
The Need for Long-Acting HIV Prevention
Women living in Kenya and South Africa describe the cultural and economic barriers to HIV prevention.
Publications
